

REMARKS

Claims 1-4, 6, and 8-10 are pending. Claims 5 and 7 have been cancelled. Claims 1, 2, 4, 6 and 8 have been amended as set forth below. No new matter is introduced thereby.

Rejection Under 35 U.S.C. §112, First Paragraph

Claims 1, 4, and 8 have been rejected as not enabled for use of the terms "solvates," "esters," "polymorphs," "prodrugs," or "metabolites." Applicants have amended claims 1, 4 and 8 accordingly by deleting those terms, and the rejection is thus believed to have been mooted.

Claims 4-7 have been rejected as not enabled for treatment of prophylaxis of any disease or disorder, mediated through muscarinic receptors, involving the respiratory, urinary and gastrointestinal systems. Applicants have amended claims 4 and 6 and deleted claims 5 and 7 accordingly, by deleting the subject matter of the rejection and by writing the limitations of claim 5 into claim 4, and the limitations of claim 7 into claim 6, and the rejection is thus believed to have been mooted.

Claim Objections

Claim 2 has been objected to for lacking delimiters between compounds, for lacking "and" after the penultimate compound name, and for lacking a period to conclude the claim. Appropriate amendments have been made to the claim.

Claims 3, 9 and 10 have been objected to as dependent from a rejected base claim, and would be allowable if rewritten in independent form, including all limitations of the base claim and any intervening claims. However, it is now submitted that the base claims are allowable, as indicated above.

CONCLUSION


It is respectfully submitted that all pending claims are currently allowable, and a Notice of Allowability and a Notice of Allowance are requested at this time.

Authorization is hereby provided to charge any required fees to Deposit Account No. 50-0912.

Respectfully submitted,

MEHTA et al.

By: _____



George E. Heibel
Reg. No. 42,648

Date: March 1, 2007

Correspondence Address:

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540

Telephone: (609) 720-5334
Facsimile: (609) 514-9779